Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden | MicrobiomeTrials
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-07-16Est. Completion: 2029-08-14
Enrollment target: 570 participants
Locations
Sun Valley Arthritis Center Ltd, Peoria, Arizona, United States
Clinical Res Of W Florida, Clearwater, Florida, United States
Clinical Research of West Florida Inc, Tampa, Florida, United States
Willow Rheumatology Wellness, Willowbrook, Illinois, United States
Clinical Research Inst of MI, Saint Clair Shores, Michigan, United States
On Site Clinical Solutions Llc, Charlotte, North Carolina, United States
RAO Research LLC, Oklahoma City, Oklahoma, United States
West Tennessee Research Institute, Jackson, Tennessee, United States
Shelby Research LLC, Memphis, Tennessee, United States
Novel Research LLC, Bellaire, Texas, United States
Arthritis Care of Texas, Corpus Christi, Texas, United States
Precision Comprehensive Clinical Research Solutions, Euless, Texas, United States
Abigail Neiman MD PA, Houston, Texas, United States
Accurate Clinical Research, League City, Texas, United States
TEKTON, Leander, Texas, United States
Arthritis Northwest PLLC, Spokane, Washington, United States
Other microbiome trials you might be interested in